DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,868,690 | +3.4% | 7,532 | 0.0% | 0.51% | +7.2% |
| Q2 2023 | $1,807,680 | -7.8% | 7,532 | -3.2% | 0.48% | -12.5% |
| Q1 2023 | $1,961,376 | -5.0% | 7,782 | 0.0% | 0.54% | -6.5% |
| Q4 2022 | $2,065,498 | +2.6% | 7,782 | -0.2% | 0.58% | -6.6% |
| Q3 2022 | $2,014,000 | -4.9% | 7,797 | -6.6% | 0.62% | +1.8% |
| Q2 2022 | $2,117,000 | -19.2% | 8,352 | -6.5% | 0.61% | -6.1% |
| Q1 2022 | $2,620,000 | +15.3% | 8,932 | +29.3% | 0.65% | +14.6% |
| Q4 2021 | $2,272,000 | +17.1% | 6,907 | +8.4% | 0.57% | +8.0% |
| Q3 2021 | $1,940,000 | +13.5% | 6,372 | 0.0% | 0.53% | +12.9% |
| Q2 2021 | $1,710,000 | +643.5% | 6,372 | +523.5% | 0.47% | +529.7% |
| Q1 2021 | $230,000 | -15.1% | 1,022 | -16.4% | 0.07% | -19.6% |
| Q4 2020 | $271,000 | +3.0% | 1,222 | 0.0% | 0.09% | -8.9% |
| Q3 2020 | $263,000 | +12.4% | 1,222 | -7.6% | 0.10% | +3.1% |
| Q2 2020 | $234,000 | +5.4% | 1,322 | -39.9% | 0.10% | +8.9% |
| Q2 2016 | $222,000 | +6.2% | 2,200 | 0.0% | 0.09% | +3.4% |
| Q1 2016 | $209,000 | +2.5% | 2,200 | 0.0% | 0.09% | +2.4% |
| Q4 2015 | $204,000 | – | 2,200 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |